In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X, Janssen Enter Oral Drug Delivery Alliance
BioMed X, Janssen Enter Oral Drug Delivery Alliance
ContractPharma
Aims to discover novel transport mechanisms which could be utilized for oral delivery of therapeutic modalities.
Visit: BioMed X Launches Drug Delivery Research Project with Janssen
BioMed X Launches Drug Delivery Research Project with Janssen
BioPharm International
The project is aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.
Visit: Crowdsourcing and open innovation in drug discovery: recent contributions and future directions
Crowdsourcing and open innovation in drug discovery: recent contributions and future directions
Drug Discovery Today
The past decade has seen significant growth in the use of ‘crowdsourcing’ and open innovation approaches to engage ‘citizen scientists’ to perform novel scientific research. Here, we quantify and summarize the current state of adoption of open innovation by major pharmaceutical companies.
Visit: BioMed X Institute completes first neuroscience research project with Boehringer Ingelheim
BioMed X Institute completes first neuroscience research project with Boehringer Ingelheim
SelectScience
Research Team BMP (Brain Microcircuits in Psychiatric Diseases) uncovered alterations in astrocyte metabolism as a major hallmark of depression
Visit: Germany-based BioMed X Institute completed its first joint research project in neuroscience with Boehringer Ingelheim.
Germany-based BioMed X Institute completed its first joint research project in neuroscience with Boehringer Ingelheim.
BioSpace
Following completion of the project, the research has now transitioned to BI for additional development. The team has validated candidate genes in several biological systems, and as a key achievement, proposes novel glial-specific drug targets for therapy of depression.
Visit: The Biomed X Institute, of Heidelberg, Germany, said it completed its first joint research neuroscience project with Boehringer Ingelheim GmbH, of Ingelheim, Germany.
The Biomed X Institute, of Heidelberg, Germany, said it completed its first joint research neuroscience project with Boehringer Ingelheim GmbH, of Ingelheim, Germany.
BioWorld
The project launched in 2016 to uncover the contribution of astrocytes, a subtype of glial cells, to molecular phenotypes in depression.
Visit: Talenten auf der Spur
Talenten auf der Spur
DER SPIEGEL, special section 'Starkes Land Baden-Württemberg' (print edition for Baden Württemberg)
Careers in the industry: The region around Heidelberg attracts top-class specialists from all over the world with quality of life, a lively international atmosphere and a wide range of jobs in research and industry. (German only)
Visit: Biotech in Deutschland – eine Branche weit unter Potenzial
Biotech in Deutschland – eine Branche weit unter Potenzial
BioSpektrum
Als bedeutender Forschungszweig in der Medizin liefert die Biotechnologie wichtige Impulse für neue Wirkstoffe, Medikamente und Diagnostika. Trotz des großen Innovationspotenzials in Deutsch land liegen hier die Investitionen in die Translation von Forschungsergebnissen in marktfähige Produkte weit hinter den internationalen Spitzenstandorten Silicon valley und Boston.
Visit: Can AI and Automation Deliver a COVID-19 Antiviral While It Still Matters?
Can AI and Automation Deliver a COVID-19 Antiviral While It Still Matters?
IEEE Spectrum
Researchers are betting that new tools can cut drug discovery from five years to six months
Visit: BioMed X Enstitüsü’nden Dr. Ebru Ercan Herbst: Şizofreni her 100 insanda 1’inde görülüyor
BioMed X Enstitüsü’nden Dr. Ebru Ercan Herbst: Şizofreni her 100 insanda 1’inde görülüyor
Independent Türkçe
From the BioMed X Institute, Dr. Ebru Ercan Herbst: Schizophrenia is seen in 1 in every 100 people. Schizophrenia, which starts between the ages of 16 and 30, causes hallucinations, delusions, and disordered thinking.
Visit: Antiviral Drug Discovery Reinvented
Antiviral Drug Discovery Reinvented
GENengnews.com
Despite countless efforts of the global scientific community to mitigate the spread of COVID-19 and its negative consequences for global health and the economy, there is an evident need for new approaches to protect humanity from future pandemics.
Visit: Wie professionelle Translation Biotechnologie-Innovationen fördert
Wie professionelle Translation Biotechnologie-Innovationen fördert
ey.com
Fortschritt im Life-Sciences-Sektor braucht mehr Förderung – zum Beispiel durch professionelle Übersetzung von der Forschung in den Markt.
Visit: Tackling the Unmet Need in Biomedical Research & Development
Tackling the Unmet Need in Biomedical Research & Development
Business Worldwide Magazine
Despite technological progress in basic medical research and steadily increasing knowledge on human diseases, the translation of research results into new therapies is still inefficient.
Visit: Head of BioMed X Wins Business Worldwide Magazine’s CEO Award
Head of BioMed X Wins Business Worldwide Magazine’s CEO Award
Yahoo Finance
The Awards seek to identify and honour the most respected C-level executives across the globe, from a comprehensive range of sectors.
Visit: Head of BioMed X Wins Business Worldwide Magazine’s CEO Award
Head of BioMed X Wins Business Worldwide Magazine’s CEO Award
Pharmaboardroom.com
The Founder and Managing Director of German biotechnology company BioMed X has been named “Biotechnology CEO Of The Year- Europe” in the Business Worldwide Magazine (BWM) 2020 CEO Awards.
Visit: Head of BioMed X Wins Business Worldwide Magazine’s CEO Award
Head of BioMed X Wins Business Worldwide Magazine’s CEO Award
seekingalpha.com
The Awards seek to identify and honour the most respected C-level executives across the globe, from a comprehensive range of sectors.
Visit: Head of BioMed X Wins Business Worldwide Magazine’s CEO Award
Head of BioMed X Wins Business Worldwide Magazine’s CEO Award
marketwatch.com
The Founder and Managing Director of German biotechnology company BioMed X has been named “Biotechnology CEO Of The Year- Europe” in the Business Worldwide Magazine (BWM) 2020 CEO Awards.
Visit: Interview with Christian Tidona, CEO of BioMed X at the London Stock Exchange Studios
Interview with Christian Tidona, CEO of BioMed X at the London Stock Exchange Studios
Business Worldwide Magazine
BioMed X founder and Managing Director, Dr. Christian Tidona, interviewed on BioMed X’ s track record by Nadira Tudor of Business Worldwide Magazine.
Visit: Leveraging synergies in pre-clinical biomedical R&D – pharmaceutical companies benefit from new innovation models
Leveraging synergies in pre-clinical biomedical R&D – pharmaceutical companies benefit from new innovation models
Word Pharma Today
As the complexity of pharmaceutical research and development increases constantly, its innovation productivity defined as the successful approval and launch of truly novel drugs and therapies, has declined since years.
Visit: German firms work together on autoimmune disorders
German firms work together on autoimmune disorders
the pharmaletter
Germany’s BioMed X has unveiled a new joint research group, in collaboration with Merck KGaA.
Visit: BioMed X Reaches Milestone in Respiratory Disease Research Collaboration with Boehringer Ingelheim
BioMed X Reaches Milestone in Respiratory Disease Research Collaboration with Boehringer Ingelheim
BioSpace
BioMed X announced today the successful completion of their first joint research project with Boehringer Ingelheim in the fields of chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).